Sygnature Discovery (Group)

https://www.sygnaturediscovery.com

Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. Private equity-backed since 2017, the company operates fully enabled research facilities in Nottingham and Alderley Park, UK, housing more than 400 research scientists (over 80% of whom hold a PhD), and has an office presence in Cambridge, MA, and South San Francisco, CA, in the US. Their experienced drug-hunters possess all the professional skills and know-how required to undertake the most demanding of research programs, and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Sygnature’s in vivo pharmacology arm was formed by the incorporation of RenaSci, acquired in 2018, into Sygnature’s fully integrated drug discovery platform. In 2020 Sygnature added to this with the acquisitions of in vivo oncology firm Alderley Oncology and DMPK provider XenoGesis. Since 2011, 37 compounds discovered by Sygnature for customers have entered pre-clinical development and, so far, 20 of these have progressed to clinical trials (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade, and in the last year has won both the Medilink Outstanding Achievement Award and the Bionow Company of the Year Award. *

	Start	2011-09-05 renamed
	Today	Sygnature Discovery Ltd.
	Predecessor	Sygnature Chemical Services Ltd.
	Industry	drug discovery services
	Industry 2	ADME services
	Person	Hirst, Simon (Sygnature Discovery 201112 CEO + Founder)
	Person 2	Lindstrom, Anders (Andy) (Sygnature Discovery 201807c– Director of Marketing before Siemens + Experian)

	Region	Nottingham, Nottinghamshire
	Country	United Kingdom (GB)
	Street	Pennyfoot Street BioCity Nottingham, The Discovery Building
	City	NG1 1GR Nottingham
	Tel	+44-115-941-5401
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2022-04-26)

		* Document for »About Section«: Sygnature Discovery Ltd.. (4/26/22). "Press Release: Sygnature Discovery Acquires Peak Proteins, to Strengthen Its Drug Discovery Capabilities". Nottingham.

		Record changed: 2023-07-10